glp 1 asa Advises No Longer Holding GLP-1 Agents Prior to Surgery for Most Patients ASA: Hold GLP-1 Agonists Before

GLP-1 Receptor Activation: According to published research on GLP-1 agonists: Stimulates insulin secretion in a glucose-dependent manner (meaning it enhances insulin release when blood glucose is elevated, not when it's already low-this reduces hypoglycemia risk) Slows gastric emptying (food stays in your stomach longer, creating prolonged feelings of fullness) Influences appetite regulation in the brain (reduces hunger signals, increases satiety signals) May reduce food cravings, particularly for high-fat, high-sugar foods GIP Receptor Activation (The Second Mechanism): GIP is another incretin hormone that: Also stimulates insulin secretion in a glucose-dependent manner May influence fat metabolism and how the body stores or burns fat (research ongoing) Potentially affects energy expenditure (how many calories you burn at rest) May work synergistically with GLP-1 for enhanced metabolic effects The combination of both receptor pathways appears to produce stronger weight loss effects than GLP-1 activation alone

To frame potential downside, we can calculate conservative , back-of-the-envelope , high-end estimates

I/R injury-induced dysbiosis can result in reduced SCFA production, contributing to increased neuroinflammation and BBB breakdown

GLP-1, or glucagon-like peptide-1, is a hormone from the small intestine released when we eat